Premium
Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis
Author(s) -
Napolitano Maddalena,
Gallo Lucia,
Megna Matteo,
Fabbrocini Gabriella,
Nocerino Mariateresa,
Abategiovanni Luisa,
Patruno Cataldo
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12900
Subject(s) - medicine , certolizumab pegol , psoriatic arthritis , dermatology , monoclonal antibody , hypersensitivity reaction , immunology , arthritis , psoriasis , antibody , rheumatoid arthritis , adalimumab
The pathogenic mechanism of hypersensitivity reactions (HSRs) to monoclonal antibodies is not fully understood. HSRs can occur after the first exposure or multiple exposures and include acute infusion reactions induced by cytokine release, besides Type I, Type III, and Type IV reactions.). We reported a case of anaphylactic reaction to certolizumab pegol in a patient affected by psoriatic arthritis and a possible management of this condition.